Tag Archives: Tykerb

Neratinib for breast cancer – the key is managing gastrointestinal toxicity

Neratinib is an irreversible tyrosine-kinase inhibitor of EGFR (epidermal growth factor receptor), as well as HER1, HER2, and HER4. It is being developed for patients with breast cancer. It blocks many signal transduction pathways that result in proliferation and invasion, leading to cell cycle arrest and apoptosis. (Figures 1 and 2). Continue reading

Oncodesign and Bristol Myers Squibb Enter Collaboration for Novel Kinase Inhibitors

Bristol-Myers Squibb recruited French biotech Oncodesign to help it find new ways of attacking tumors, signing an early-stage agreement in hopes of spotlighting some promising projects. Continue reading